Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score
Table 1
Baseline clinical characteristics of BTC patients (, %).
Characteristics
No. of patients (, %)
Overall ()
The good LIPI ()
The intermediate LIPI ()
The poor LIPI ()
Median age (range), years
59 (24-91)
55.5 (24-70)
61 (42-80)
60 (44-91)
Sex
Female
43 (39.1)
17 (44.7)
21 (37.5)
5 (36.1)
Male
67 (60.9)
21 (55.3)
35 (62.5)
11 (68.8)
Smoking history
Yes
36 (32.7)
12 (31.6)
16 (28.6)
8 (50.0)
No
74 (67.3)
26 (68.4)
40 (71.4)
8 (50.0)
Smoking exposure
>30 packs per year
23 (20.9)
10 (26.3)
8 (14.3)
5 (31.3)
≤30 packs per year
87 (79.1)
28 (73.7
48 (85.7)
11 (68.8)
History of diabetes
Yes
19 (17.3)
6 (15.8)
10 (17.9)
3 (18.8)
No
91 (82.7)
32 (84.2)
46 (82.1)
13 (81.3)
Tumor type
CC
88 (80.0)
32 (84.2)
45 (80.4)
11 (68.8)
GBC
22 (20.0)
6 (15.8)
11 (19.6)
5 (31.3)
Liver metastasis
Present
46 (41.8)
18 (47.4)
18 (32.1)
10 (62.5)
Absent
64 (58.2)
20 (52.6)
38 (67.9)
6 (37.5
Number of metastatic sites
≥2
39 (35.5)
14 (36.8)
17 (30.4)
8 (50.0)
<2
71 (64.5)
24 (63.2)
39 (69.6)
8 (50.0)
Lines of immunotherapy
≥2
31 (28.2)
8 (21.1)
17 (69.6)
6 (37.5)
<2
79 (71.8)
30 (78.9)
39 (30.4)
10 (62.5)
ECOG PS
≥2
6 (5.5)
1 (2.6)
2 (3.6)
3 (18.8)
0-1
104 (94.5)
37 (97.4)
54 (96.4)
13 (81.3)
PD-1 inhibition agent
Nivolumab
34 (30.9)
14 (36.8)
16 (28.6)
4 (25.0)
Pembrolizumab
11 (10.0)
2 (5.3)
4 (7.1)
5 (31.3)
Others
65 (59.1)
22 (57.91)
36 (64.3)
7 (43.8)
ICIs combined with other therapies
Monotherapy
20 (18.2)
8 (21.1)
9 (16.1)
3 (18.8)
Chemotherapy
73 (66.4)
25 (65.8)
37 (66.1)
11 (68.8)
Target therapy
9 (8.2)
4 (10.5)
5 (8.9)
0 (0)
Chemotherapy and target therapy
8 (7.3)
1 (2.6)
5 (8.9)
2 (12.5
Treatment-related adverse events
Present
76 (69.1)
25 (65.8)
39 (69.6)
12 (75.0)
Absent
34 (30.9)
13 (34.2)
17 (30.4)
4 (25.0)
CC: GBC: ECOG PS: Eastern Cooperative Oncology Group performance status scores; PD-1: programmed cell death-1; ICIs: immune checkpoint inhibitors.
